以灯盏细辛注射液病历专项点评为例浅谈辅助用药管理经验
|
摘要
目的:分析我院灯盏细辛注射液的使用情况,为辅助用药管理工作提供参考。方法:通过对2017年9月—2017年11月随机抽取的187例灯盏细辛注射液病历进行专项点评,分析用药的合理性。结果:灯盏细辛注射液用药总不合理率为39.04%,不合理原因主要为适应症不适宜、无适应症用药及用法用量不合理。进行专项点评工作前后不合理率有所下降。结论:专项点评工作可增强辅助用药的管理,促进灯盏花注射液临床合理用药。
Objective:To analysis the rational use of dengzhanxixin injection and to provide reference for the management of auxiliary medication in the hospital. Methods: 187 cases treated with dengzhanxixin injection in three months were randomly selected to special comments. Results: The unreasonable rate of the dengzhanxixin injection was 39.04%, the main reasons for the unreasonableness are the unsuitability of indications, the unreasonableness of indications and dosage. The clinical rational use of medicine was promoted after special comments. Conclusion:The specialized comments can enhance the managent of the adjuvant drugs and rationality of the clinical use of dengzhanxixin injection.
Objective:To analysis the rational use of dengzhanxixin injection and to provide reference for the management of auxiliary medication in the hospital. Methods: 187 cases treated with dengzhanxixin injection in three months were randomly selected to special comments. Results: The unreasonable rate of the dengzhanxixin injection was 39.04%, the main reasons for the unreasonableness are the unsuitability of indications, the unreasonableness of indications and dosage. The clinical rational use of medicine was promoted after special comments. Conclusion:The specialized comments can enhance the managent of the adjuvant drugs and rationality of the clinical use of dengzhanxixin injection.
引文
[1]韩爽,钟敏涛,李锦,等.我国辅助用药应用现状及管理对策初探[J].中国药学杂志,2016,51(8):678-682.
[2]国家药典委员会.中华人民共和国药典(2015年版)一部[S].北京:中国医药科技出版社, 2015,873.
[3]郭文平.灯盏细辛注射液的临床研究及应用[J].中西医结合心脑血管病杂志,2011,9(1):96-98.
[4]李莉,宋海燕,孙世光.灯盏细辛注射液临床使用合理性与安全性再评价研究[J].中国临床药理学杂志,2015,31(15):1543-1545.
[5]韩涛,谢雁鸣,黎元元,等.鹿瓜多肽注射液治疗骨质疏松症人群特征及联合用药分析[J].中药药理与临床,2017,33(04):154-157.
[6]胡茂忠,李轶津.灯盏细辛注射液预防髋关节置换术后下肢深静脉栓塞[J].广东医学,2004,25(9):1104.
[7]郑雪,李静,司继刚.中药注射剂超适应证用药情况分析[J].中国医院用药评价与分析,2014,14(7):624-627.
[8]杨世红.骨科活血化瘀类中药注射剂不合理应用状况调查研究[J].北方药学,2017,14(7):158-159.
[9]国家中医药管理局医政司.中成药临床应用指导原则[S].国中医药医政发[2010]30号.2010-06-11.
[10]中华人民共和国国家卫生和计划生育委员会.关于控制公立医院医疗费用不合理增长的若干意见[J].中国实用乡村医生杂志, 2015, 22(23):7-9.
[2]国家药典委员会.中华人民共和国药典(2015年版)一部[S].北京:中国医药科技出版社, 2015,873.
[3]郭文平.灯盏细辛注射液的临床研究及应用[J].中西医结合心脑血管病杂志,2011,9(1):96-98.
[4]李莉,宋海燕,孙世光.灯盏细辛注射液临床使用合理性与安全性再评价研究[J].中国临床药理学杂志,2015,31(15):1543-1545.
[5]韩涛,谢雁鸣,黎元元,等.鹿瓜多肽注射液治疗骨质疏松症人群特征及联合用药分析[J].中药药理与临床,2017,33(04):154-157.
[6]胡茂忠,李轶津.灯盏细辛注射液预防髋关节置换术后下肢深静脉栓塞[J].广东医学,2004,25(9):1104.
[7]郑雪,李静,司继刚.中药注射剂超适应证用药情况分析[J].中国医院用药评价与分析,2014,14(7):624-627.
[8]杨世红.骨科活血化瘀类中药注射剂不合理应用状况调查研究[J].北方药学,2017,14(7):158-159.
[9]国家中医药管理局医政司.中成药临床应用指导原则[S].国中医药医政发[2010]30号.2010-06-11.
[10]中华人民共和国国家卫生和计划生育委员会.关于控制公立医院医疗费用不合理增长的若干意见[J].中国实用乡村医生杂志, 2015, 22(23):7-9.